These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35443520)

  • 1. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
    Das D; Mukhopadhyay P; Banerjee D
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
    N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
    Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
    Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
    Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
    Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
    Paules CI; Wang J; Tomashek KM; Bonnett T; Singh K; Marconi VC; Davey RT; Lye DC; Dodd LE; Yang OO; Benson CA; Deye GA; Doernberg SB; Hynes NA; Grossberg R; Wolfe CR; Nayak SU; Short WR; Voell J; Potter GE; Rapaka RR
    Ann Intern Med; 2024 Mar; 177(3):343-352. PubMed ID: 38408357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
    Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
    Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
    Vitiello A; Ferrara F
    Mol Biol Rep; 2022 Jan; 49(1):827-831. PubMed ID: 34839450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
    Kelton K; Klein T; Murphy D; Belger M; Hille E; McCollam PL; Spiro T; Burge R
    Adv Ther; 2022 Jan; 39(1):562-582. PubMed ID: 34807369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials.
    Lin DY; Wang J; Gu Y; Zeng D
    Clin Trials; 2024 Aug; 21(4):500-506. PubMed ID: 38618926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
    Chatterjee B; Thakur SS
    Front Immunol; 2022; 13():830990. PubMed ID: 35634324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
    Titanji BK; Farley MM; Mehta A; Connor-Schuler R; Moanna A; Cribbs SK; O'Shea J; DeSilva K; Chan B; Edwards A; Gavegnano C; Schinazi RF; Marconi VC
    Clin Infect Dis; 2021 Apr; 72(7):1247-1250. PubMed ID: 32597466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.
    Vitiello A; Ferrara F
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Jan; 395(1):99-104. PubMed ID: 34669002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EUA for baricitinib (Olumiant) for COVID-19.
    Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
    Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
    Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
    Goletti D; Cantini F
    N Engl J Med; 2021 Mar; 384(9):867-869. PubMed ID: 33657299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.